400 related articles for article (PubMed ID: 33324011)
1. PKC downregulation upon rapamycin treatment attenuates mitochondrial disease.
Martin-Perez M; Grillo AS; Ito TK; Valente AS; Han J; Entwisle SW; Huang HZ; Kim D; Yajima M; Kaeberlein M; Villén J
Nat Metab; 2020 Dec; 2(12):1472-1481. PubMed ID: 33324011
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.
Johnson SC; Yanos ME; Kayser EB; Quintana A; Sangesland M; Castanza A; Uhde L; Hui J; Wall VZ; Gagnidze A; Oh K; Wasko BM; Ramos FJ; Palmiter RD; Rabinovitch PS; Morgan PG; Sedensky MM; Kaeberlein M
Science; 2013 Dec; 342(6165):1524-8. PubMed ID: 24231806
[TBL] [Abstract][Full Text] [Related]
3. Acarbose suppresses symptoms of mitochondrial disease in a mouse model of Leigh syndrome.
Bitto A; Grillo AS; Ito TK; Stanaway IB; Nguyen BMG; Ying K; Tung H; Smith K; Tran N; Velikanje G; Urfer SR; Snyder JM; Barton J; Sharma A; Kayser EB; Wang L; Smith DL; Thompson JW; DuBois L; DePaolo W; Kaeberlein M
Nat Metab; 2023 Jun; 5(6):955-967. PubMed ID: 37365290
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin enhances survival in a Drosophila model of mitochondrial disease.
Wang A; Mouser J; Pitt J; Promislow D; Kaeberlein M
Oncotarget; 2016 Dec; 7(49):80131-80139. PubMed ID: 27741510
[TBL] [Abstract][Full Text] [Related]
5. Regional metabolic signatures in the Ndufs4(KO) mouse brain implicate defective glutamate/α-ketoglutarate metabolism in mitochondrial disease.
Johnson SC; Kayser EB; Bornstein R; Stokes J; Bitto A; Park KY; Pan A; Sun G; Raftery D; Kaeberlein M; Sedensky MM; Morgan PG
Mol Genet Metab; 2020 Jun; 130(2):118-132. PubMed ID: 32331968
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy.
Bornstein R; James K; Stokes J; Park KY; Kayser EB; Snell J; Bard A; Chen Y; Kalume F; Johnson SC
Neurobiol Dis; 2022 Feb; 163():105594. PubMed ID: 34933094
[TBL] [Abstract][Full Text] [Related]
7. Neurometabolic disease: Treating mitochondrial diseases with mTOR inhibitors--a potential treatment for Leigh syndrome?
Geach T
Nat Rev Neurol; 2014 Jan; 10(1):2. PubMed ID: 24296657
[No Abstract] [Full Text] [Related]
8. Medicine. A common pathway for a rare disease?
Vafai SB; Mootha VK
Science; 2013 Dec; 342(6165):1453-4. PubMed ID: 24357304
[No Abstract] [Full Text] [Related]
9. Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses.
Felici R; Buonvicino D; Muzzi M; Cavone L; Guasti D; Lapucci A; Pratesi S; De Cesaris F; Luceri F; Chiarugi A
Neuropharmacology; 2017 May; 117():74-84. PubMed ID: 28161373
[TBL] [Abstract][Full Text] [Related]
10. The NDUFS4 Knockout Mouse: A Dual Threat Model of Childhood Mitochondrial Disease and Normative Aging.
Grillo AS; Bitto A; Kaeberlein M
Methods Mol Biol; 2021; 2277():143-155. PubMed ID: 34080150
[TBL] [Abstract][Full Text] [Related]
11. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease.
de Haas R; Das D; Garanto A; Renkema HG; Greupink R; van den Broek P; Pertijs J; Collin RWJ; Willems P; Beyrath J; Heerschap A; Russel FG; Smeitink JA
Sci Rep; 2017 Sep; 7(1):11733. PubMed ID: 28916769
[TBL] [Abstract][Full Text] [Related]
13. Targeting NAD
Lee CF; Caudal A; Abell L; Nagana Gowda GA; Tian R
Sci Rep; 2019 Feb; 9(1):3073. PubMed ID: 30816177
[TBL] [Abstract][Full Text] [Related]
14. Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome.
Siegmund SE; Yang H; Sharma R; Javors M; Skinner O; Mootha V; Hirano M; Schon EA
Hum Mol Genet; 2017 Dec; 26(23):4588-4605. PubMed ID: 28973153
[TBL] [Abstract][Full Text] [Related]
15. mTOR (Mechanistic Target of Rapamycin) Inhibition Decreases Mechanosignaling, Collagen Accumulation, and Stiffening of the Thoracic Aorta in Elastin-Deficient Mice.
Jiao Y; Li G; Li Q; Ali R; Qin L; Li W; Qyang Y; Greif DM; Geirsson A; Humphrey JD; Tellides G
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1657-1666. PubMed ID: 28751568
[TBL] [Abstract][Full Text] [Related]
16. Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy.
Manning A; Han V; Stephens A; Wang R; Bush N; Bard M; Ramirez JM; Kalume F
Neurobiol Dis; 2023 Oct; 187():106288. PubMed ID: 37704057
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
Nguyen LH; Brewster AL; Clark ME; Regnier-Golanov A; Sunnen CN; Patil VV; D'Arcangelo G; Anderson AE
Epilepsia; 2015 Apr; 56(4):636-46. PubMed ID: 25752454
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation.
Zhao Y; Zhao MM; Cai Y; Zheng MF; Sun WL; Zhang SY; Kong W; Gu J; Wang X; Xu MJ
Kidney Int; 2015 Oct; 88(4):711-21. PubMed ID: 26061549
[TBL] [Abstract][Full Text] [Related]
19. Ndufs4 KO mice: A model to study comorbid mood disorders associated with mitochondrial dysfunction.
van Rensburg DJ; Lindeque Z; Harvey BH; Steyn SF
Pharmacol Biochem Behav; 2024 Jan; 234():173689. PubMed ID: 38070656
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous inhibition of atypical protein kinase‑C and mTOR impedes bladder cancer cell progression.
Patel R; Islam SA; Bommareddy RR; Smalley T; Acevedo-Duncan M
Int J Oncol; 2020 Jun; 56(6):1373-1386. PubMed ID: 32236625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
